Hibercell, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.hibercell.com
A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06234605
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05484011
- Locations
- 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05159778
- Locations
- 🇺🇸
HealthPartners Cancer Research Center, Saint Louis Park, Minnesota, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Miami and Clinics -Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05121948
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- HiberCell, Inc.
- Registration Number
- NCT04995094
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04834778
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸HealthPartners Cancer Care Center, Saint Paul, Minnesota, United States
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
- Conditions
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT03246685
- Locations
- 🇺🇸
Northwestern Medical Specialties, PLLC, Tacoma, Washington, United States
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT02981303
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Arizona Center for Cancer Care, Avondale, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT01309126
- Locations
- 🇺🇸
Ellis Fischel Cancer Center at University of Missouri- Columbia, Columbia, Missouri, United States
🇺🇸Hematology and Oncology Associates of Central NY, East Syracuse, New York, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00912327
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Memorial Sloane-Kettering Cancer Research Center, New York, New York, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States